From: International variation in the management of severe COVID-19 patients
Numbers (%) or median (interquartile ranges) | Total, 1001 respondents |
---|---|
1. Admission to the ICU of a previously healthy 39-year-old man with severe COVID-19 | |
Direct admission to the ICU | 55% |
Admission in an intermediate care unit | 34.2% |
Delayed admission to the ICU because of lack of bed | 1.3% |
Patient stays in the emergency department | 0.8% |
Patient admitted in the wards | 8.8% |
2. Initial oxygenation strategy | |
I increase the oxygen flow to 15 l/min keeping the face mask | 24.2% |
I change the mask for a Venturi mask | 17.5% |
I start CPAP or noninvasive ventilation | 25.5% |
I start high flow nasal oxygen | 47.1% |
I intubate the patient right away | 7.4% |
I add prone positioning on spontaneous breathing | 37.9% |
3. Optimizing oxygenation in a patient with a PF ratio of 84 4 h after intubation | |
I will give neuromuscular blockade for 24–48 h | 50.9% |
I increase and titrate PEEP to optimize recruitment | 61.4% |
I prone the patient immediately | 73.2% |
I am considering ECMO immediately | 4.7% |
Let us wait a little bit | 9.9% |
4. Regarding the initial antibiotics | |
All my patients receive a broad anti-bacterial agent | 45.3% |
I only give broad anti-bacterial agent to febrile patients | 11% |
I only give broad anti-bacterial agent if CRP or PCT are high | 4.2% |
I only give broad anti-bacterials to patients with structural lung diseases | 35.8% |
I never give broad anti-bacterial agent in severe viral infections | 3.7% |
5. Regarding initial anti-viral therapy, several options are possible | |
The level of evidence is so low that there is nothing I can give | 48.9% |
I prescribe (hydroxy)chloroquine | 42.7% |
I prescribe lopinavir/ritonavir | 17.0% |
I prescribe remdesivir | 15% |
I prescribe another anti-viral drug | 4.6% |
6. Are you starting an anti-inflammatory therapy? | |
No | 52.4% |
Yes IL-1 or IL-6 blockade | 24.8% |
Yes, complement blockade | 1.4% |
Yes, steroids | 31.5% |
Yes, another anti-inflammatory drug | 2.4% |